Crossmark

Preclinical evaluation of gefitinib and betulin-loaded surface functionalized liposomes for the treatment of hepatocellular carcinoma via asialoglycoprotein receptor targeting

Crossref DOI link: https://doi.org/10.1007/s00210-026-04999-2

Published Online: 2026-01-30

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Singh, Amita

Kumar, Vipin

Prachi, Km

Rajan, Nitin

Singh, Sanjay

Rajamanickam, Vijayakumar Mahalingam
Funding

Funding for this research was provided by:

Indian Council of Medical Research (3/2/2/85/2022-NCD-III)
License Information

Text and Data Mining valid from 2026-01-30

Version of Record valid from 2026-01-30
More Information

Article History

Received: 9 October 2025

Accepted: 8 January 2026

First Online: 30 January 2026

Declarations

:

: The protocol was approved by the Institutional Animal Ethics Committee of MET Faculty of Pharmacy for animal experimentation (METFOP/IAEC/01/25).

: The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

: Not applicable.

Document is current

Any future updates will be listed below